Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

Digestive and Liver Disease

Volumn 33, Issue 7, 2001, Pages 600-606

  Tonini, M ^a   Vigneri, S ^a,b   Savarino, V ^a,c   Scarpignato, C ^a,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Acid related disorders; Clinical pharmacology; Esomeprazole; Proton pump inhibitors

Indexed keywords

CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; RABEPRAZOLE; WARFARIN;

ABDOMINAL PAIN; ARTICLE; CHIRALITY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE CONTROL; DISEASE MANAGEMENT; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; DRUG PURITY; DRUG SAFETY; ENANTIOMER; FEMALE; HEADACHE; HELICOBACTER PYLORI; HUMAN; HYPERACTIVITY; ISOMERISM; MALE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STOMACH ACID; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; DRUG INTERACTIONS; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS; ZOLLINGER-ELLISON SYNDROME;

EID: 0034781863     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80115-8     Document Type: Article

References (41)

1. 2-receptor antagonists and proton pump inhibitors for the practising physician
2. Proton pump inhibitors - Pharmacology and rationale for use in gastrointestinal disorders
3. Esomeprazole
4. + ATPase
5. + ATPase
6. + ATPase with extracytoplasmic thiol reagents
7. +-adenosin triphosphatase alpha subunit and its effect on inhibition of rat gastric secretion
8. Rabeprazole
9. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
10. Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis
11. Drug therapy: Omeprazole
12. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders
13. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid related disorders
14. Esomeprazole magnesium
15. Asymmetric synthesis of esomeprazole
16. Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy
17. Chiral switch, a successful way for developing drugs: Example of esomeprazole
18. Improving on PPI-based therapy of GORD
19. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease
20. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
21. Pharmacokinetics (PK) and effect of pentagastrin stimulated peak acid output (PAO) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
22. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg
23. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg
24. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg
25. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
26. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
27. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric coated granules
28. max of esomeprazole on acid secretion and intragastric pH
29. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
30. Pharmacokinetics of esomeprazole in patients with liver cirrhosis
31. Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathological conditions
32. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
33. Pharmacokinetic study of esomeprazole in the elderly
34. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole
35. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease
36. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
37. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
38. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux of efficacy and safety
39. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis
40. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month study, randomized, double-blind, placebo-controlled study of efficacy and safety
41. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients